Apheon brings onboard Unigestion Private Equity as partner in continued journey with Ortivity
- Private equity
- Press releases
Apheon, a pan-European private equity investor, is pleased to announce a further investment in its portfolio company Ortivity (“Ortivity” or the “Company”), Germany’s leading outpatient orthopaedic care platform. The contemplated transaction provides a partial exit for existing Ortivity shareholders while bringing onboard Unigestion Private Equity, a leading private equity firm focused on the mid-market, and selected new Apheon investors, thereby reinforcing Apheon’s overall exposure to the Company. The approximate EUR 200 million capital injection marks the successful completion of a targeted partner search. Through its private equity funds, Unigestion Private Equity acquires a significant minority stake in Ortivity, while Apheon remains the lead investor.
Founded in 2022 by a group of leading physicians, Dr. med. Reinhard Wichels and Apheon, Ortivity has over the past four years developed rapidly into one of Germany’s most prominent outpatient healthcare platforms. The Company operates over 100 sites across three regional clusters in Germany, offering a full spectrum of orthopaedic services, including diagnostics, anaesthesia, surgery, prevention, and aftercare. Ortivity’s physician partnership model and emphasis on clinical excellence have positioned the Group as a trusted provider and builder of modern outpatient infrastructure. The Company is equally owned by physicians and capital providers.
To facilitate and further drive the ambitious growth plans, Apheon ran a targeted search to bring onboard a new financial partner. Through its private equity funds, Unigestion Private Equity’s additional capital will support Ortivity’s ongoing investments in Germany, prioritizing the enhancement of its integrated, physician-led care model. The transaction marks a significant milestone for the Company as it enters its next phase of growth with an expanded investor base. Apheon and Unigestion Private Equity have plans to further grow the Company within the existing regional clusters, and to establish new clusters, with the aim to transition Germany’s orthopaedic market towards a more modern, outpatient model.
Nils Lüssem, Partner at Apheon, and Sebastian Walter, Director at Apheon, commented: “We are pleased to welcome Unigestion as a trusted partner. During our search, Unigestion distinguished itself as collaborative, experienced, entrepreneurial and committed to long-term growth – we are delighted to have found such a partner. Since its founding by Apheon and leading physicians, Ortivity has quickly evolved into a leading provider of orthopaedic outpatient care in Germany. Partnering with Unigestion and other selected investors will ensure we have the necessary stable capital to sustain our growth and continue investing in top-quality patient care.”
Philipp Scheier, Partner at Unigestion Private Equity, commented: “We have been very impressed by Ortivity’s development since its inception in 2022. Its rapid growth is a strong testament to the hard work of the Company’s physicians, management team and Apheon, who have established a leading, high-quality and patient-centred provider of orthopaedic outpatient care solutions. I am looking forward to working together with Ortivity and Apheon to support the next chapter of this unique success story.”
Dr. Andreas Hartung, current Co-CEO, commented: “What we have built over the past four years is truly unique and Unigestion realised this right from the start of our partner search.” Dr. med. Michael Thorwarth, newly joined CEO of Ortivity, commented: “I am delighted that the start of my tenure as CEO coincides with the strengthening of the capital base of Ortivity. This marks a significant milestone as we continue to build a powerful network dedicated to innovation in musculoskeletal care. I was drawn to Ortivity by its forward-thinking vision — the seamless integration of prevention, diagnostics, and both conservative and surgical therapies. I look forward to working closely with our orthopaedic and neurosurgical specialists, as well as our dedicated practice teams, to further develop this model. Together, we aim to set new standards in treatment quality and patient-centred service, delivering measurable benefits to those we serve.”
Markus Schneppenheim, Head of the Ortivity Medical Board, practicing physician at the OGPaedicum and co-founder of Ortivity, commented: “Ortivity is the market leader in modern outpatient orthopaedic solutions in Germany. We will now accelerate the expansion of existing clusters and enable the dynamic transfer of concepts to other regions. We are very pleased to continue our collaboration with Apheon and remain fully committed to the joint project.”
Dr. med. Reinhard Wichels, physician, investor and co-founder of Ortivity: “It has been an exciting journey so far. Ortivity has not only become the largest orthopaedic outpatient platform in Germany, but also a visible thought leader on how physician networks can contribute to closing gaps in access and quality of care delivery.”
The transaction is subject to customary regulatory approvals. Houlihan Lokey acted as the exclusive financial advisor to Apheon.
For further information please email us at: corporatecommunicationteam@unigestion.com
* Unigestion Private Equity refers to the commercial name of the group, including Unigestion SA the investment manager
Important Information
Unigestion Private Equity is the trading name of Unigestion S.A.
INFORMATION ONLY FOR YOU
This document has been prepared for your information only and must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person without the prior written consent of Unigestion. It is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of, or domiciled or located in, any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
RELIANCE ON UNIGESTION
There is no guarantee that Unigestion will be successful in achieving any investment objectives. An investment strategy contains risks, including the risk of complete loss. Except where otherwise specifically noted, the information contained herein, including performance data and assets under management, relates to the entire affiliated group of Unigestion entities over time. Such information is intended to provide you with background regarding the services, investment strategies and personnel of the Unigestion entities. No guarantee is made that all or any of the individuals involved in generating the performance on behalf of one or more Unigestion entities will be involved in managing any specific client account on behalf of another Unigestion entity.
NOT A RECOMMENDATION OR OFFER
This is a promotional statement of our investment philosophy and services only in relation to the subject matter of this presentation. It constitutes neither investment advice nor recommendation. This document represents no offer, solicitation or suggestion of suitability to subscribe in either the investment vehicles to which it refers or to any securities or financial instruments described herein. Any such offer to sell or solicitation of an offer to purchase shall be made only by formal offering documents, which include, among others, a confidential offering memorandum, limited partnership agreement (if applicable), investment management agreement (if applicable), operating agreement (if applicable), and related subscription documents (if applicable). Such documentation contains additional information material to any decision to invest. Please contact your professional adviser/consultant before making an investment decision. Reference to specific securities should not be construed as a recommendation to buy or sell such securities and is included for illustration purposes only.
RISKS
Where possible we aim to disclose the material risks pertinent to this document. The views expressed in this document do not purport to be a complete description of the securities, markets and developments referred to in it. Unigestion maintains the right to delete or modify information without prior notice. The risk management practices and methods described herein are for illustrative purposes only and are subject to modification.
Investors shall conduct their own analysis of the risks (including any legal, regulatory, tax or other consequences) associated with an investment and should seek independent professional advice. Some of the investment strategies or financial instruments described or alluded to herein may be construed as high risk and not readily realisable investments, and may experience substantial & sudden losses including total loss of investment. These are not suitable for all types of investors. Unigestion has the ability in its sole discretion to change the strategies described herein.
PAST PERFORMANCE
Past performance is not a reliable indicator of future results, the value of investments, can fall as well as rise, and there is no guarantee that your initial investment will be returned. If performance is shown gross of management fees, you should be aware that the inclusion of fees, costs and charges will reduce investment returns. Returns may increase or decrease as a result of currency fluctuations.
NO INDEPENDENT VERIFICATION OR REPRESENTATION
No separate verification has been made as to the accuracy or completeness of the information herein. Data and graphical information herein are for information only and may have been derived from third party sources. Unigestion takes reasonable steps to verify, but does not guarantee, the accuracy and completeness of information from third party sources. As a result, no representation or warranty, expressed or implied, is or will be made by Unigestion in this respect and no responsibility or liability is or will be accepted. All information provided here is subject to change without notice. It should only be considered current as of the date of publication without regard to the date on which you may access the information. An investment with Unigestion, like all investments, contains risks, including total loss for the investor.
FORWARD-LOOKING STATEMENTS
This document may contain forward-looking statements, including observations about markets and industry and regulatory trends as of the original date of this document. Forward-looking statements may be identified by, among other things, the use of words such as “expects,” “anticipates,” “believes,” or “estimates,” or the negatives of these terms, and similar expressions. Forward-looking statements reflect Unigestion’s views as of such date with respect to possible future events and are subject to a number of risks and uncertainties, including, but not limited to, the impact of competitive products, market acceptance risks and other risks. Actual results could differ materially from those in the forward-looking statements as a result of factors beyond a strategy’s or Unigestion’s control. You are cautioned not to place undue reliance on such statements. No party has an obligation to update any of the forward-looking statements in this document
TARGET RETURNS
Targeted returns reflect subjective determinations by Unigestion based on a variety of factors, including, among others, internal modeling, investment strategy, prior performance of similar products (if any), volatility measures, risk tolerance and market conditions. Target returns and/or forecasts are based on Unigestion’s analytics including upside, base and downside scenarios and might include, but are not limited to, criteria and assumptions such as macro environment, enterprise value, turnover, EBITDA, debt, financial multiples and cash flows. Targeted returns are not intended to be actual performance and should not be relied upon as an indication of actual or future performance.
If target returns, forecasts or projections are shown gross of management fees, the inclusion of fees, costs and charges will reduce such numbers.
USE OF INDICES
Information about any indices shown herein is provided to allow for comparison of the performance of the strategy to that of certain well-known and widely recognized indices. There is no representation that such index is an appropriate benchmark for such comparison. You cannot invest directly in an index and the indices represented do not take into account trading commissions and/or other brokerage or custodial costs. The volatility of the indices may be materially different from that of the strategy. In addition, the strategy’s holdings may differ substantially from the securities that comprise the indices shown.
HYPOTHETICAL, BACKTESTED OR SIMULATED PERFORMANCE
Hypothetical, backtested or simulated performance is not an indicator of future actual results and has many inherent limitations. The results reflect performance of a strategy not currently offered to any investor and do not represent returns that any investor actually attained. One of the limitations of hypothetical performance results is that they are generally prepared with the benefit of hindsight.
Hypothetical performance may use, among other factors, historical financials (turnover, EBITDA, debit, financial multiples), historical valuations, macro variables and fund manager variables. Hypothetical results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Changes in these assumptions may have a material impact on the hypothetical (backtested/simulated) returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions.
This information is provided for illustrative purposes only. Specifically, hypothetical (backtested/simulated) results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk in actual trading. For example, the ability to withstand losses or to adhere to a particular trading program in spite of trading losses are material points which can also adversely affect actual trading results. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized.
If hypothetical, backtested or simulated performance is shown gross of management fees, the inclusion of fees, costs and charges will reduce such numbers.
ASSESSMENTS
Unigestion may, based on its internal analysis, make assessments of a company’s future potential as a market leader or other success. There is no guarantee that this will be realised.
Legal Entities Disseminating This Document
UNITED KINGDOM
This material is disseminated in the United Kingdom by Unigestion PE (UK) Ltd., which is authorized and regulated by the Financial Conduct Authority (“FCA”). This information is intended only for professional clients and eligible counterparties, as defined in MiFID directive and has therefore not been adapted to retail clients.
UNITED STATES
In the United States, Unigestion is present and offers its services in the United States as Unigestion (US) Ltd, which is registered as an investment advisor with the U.S. Securities and Exchange Commission (“SEC”) and/or as Unigestion (UK) Ltd., which is registered as an investment advisor with the SEC. All inquires from investors present in the United States should be directed to clients@unigestion.com. This information is intended only for institutional clients that are qualified purchasers as defined by the SEC and has therefore not been adapted to retail clients.
EUROPEAN UNION
This material is disseminated in the European Union by Unigestion Asset Management (France) SA which is authorized and regulated by the French “Autorité des Marchés Financiers” (“AMF”). This information is intended only for professional clients and eligible counterparties, as defined in the MiFID directive and has therefore not been adapted to retail clients.
CANADA
This material is disseminated in Canada by Unigestion Asset Management (Canada) Inc. which is registered as a portfolio manager and/or exempt market dealer in nine provinces across Canada and also as an investment fund manager in Ontario, Quebec and Newfoundland & Labrador. Its principal regulator is the Ontario Securities Commission (“OSC”). This material may also be distributed by Unigestion SA which has an international advisor exemption in Quebec, Saskatchewan and Ontario. Unigestion SA’s assets are situated outside of Canada and, as such, there may be difficulty enforcing legal rights against it.
SWITZERLAND
This material is disseminated in Switzerland by Unigestion SA which is authorized and regulated by the Swiss Financial Market Supervisory Authority (“FINMA”).
Related insight
- Private equity
- Press releases
Apheon, a pan-European private equity investor, is pleased to announce a further investment in its portfolio company Ortivity (“Ortivity” or the “Company”), Germany’s leading outpatient orthopaedic care platform.
[…]- Private equity
- Perspectives
Easing trade tensions and a decline in the US Dollar led to a rebound in global equity markets during the second quarter, propelled largely by mega cap growth stocks and the ‘Magnificent Seven’.
[…]- Private equity
- Corporate
Welcome to the Unigestion Fireside Chat, where we sit down with our experts and explore the latest trends across the private equity industry.
[…]- Corporate
- Press releases
Unigestion Private Equity has agreed to sell its stake in Dovida to Ardian. Dovida employs some 12,000 individuals who provide home care services to those in need across Europe and Australasia.
[…]